The current disclosure provides methods for reprogramming mammalian somatic cells by regulating the expression of endogenous cellular genes. Cellular reprogramming of somatic cells can be induced by activating the transcription of embryonic stem cell-associated genes (e.g., oct3/4) and suppressing the transcription of somatic cell-specific and/or cell death-associated genes. The endogenous transcription machinery can be modulated using synthetic transcription factors (activators and suppressors), to allow for faster, and more efficient nuclear reprogramming under conditions amenable for clinical and commercial applications. The current disclosure further provides cells obtained from such methods, along with therapeutic methods for using such cells for the treatment of diseases amendable to stem cell therapy, as well as kits for such uses.

The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. “mini-brains”). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier.

An object of the present invention is to provide a material capable of further accelerating growth of pluripotent stem cells, such as pluripotent stem cells, without impairing pluripotency thereof. In other words, the invention is an agent for accelerating growth of pluripotent stem cells, containing a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, and a solvate thereof as an active ingredient; and is a method for culturing pluripotent stem cells, including culturing pluripotent stem cells in a culture medium that contains a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, and a solvate thereof.

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

A method of treating diseases with the compound of Formula I is disclosed. The compound exhibits therapeutic effect to the treatment of various diseases including neurodegenerative diseases, muscular dystrophy, and cardiovascular diseases.

The present disclosure provides compositions and methods employing stem cell-derived embryo-like structures. In some embodiments, methods of generating embryo-like tissues from stem cells and the resulting tissues are provided. In some embodiments, uses of such tissues for research, compound screening and analysis, and therapeutics are provided. Accordingly, in some embodiments, provided herein is a method for preparing embryo-like tissue, comprising: a) introducing stem cells into a microfluidic device comprising a culture channel and a plurality of fluidic channels, wherein the stem cells are introduced to the culture channel of the microfluidic device; b) contacting the stem cells with basal medium via the plurality of fluidic channels for at least 18 hours (e.g., 36 hours) to generate the embryo-like tissue.

A method of producing induced pluripotent stem cells without using a hydrogel.

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

The present invention relates to a method for preparing an induced pluripotent stem cell line from mesenchymal stem cells; and an induced pluripotent stem cell line (deposit number: KCLRF-BP-00318) obtained thereby. Specifically, the method for preparing an induced pluripotent stem cell line, of the present invention, comprises the steps of: (a) obtaining mesenchymal stem cells from a human umbilical cord; (b) forming, from the mesenchymal stem cells, a colony with a medium for dedifferentiation containing an Ecklonia cava extract; and (c) obtaining an induced pluripotent stem cell line by sub-culturing the colony. The induced pluripotent stem cell line according to the present invention was first established by the present inventors, and the pluripotent stem cell line of the present invention can be differentiated into various cells and can treat various diseases or disorders through cell transplant therapy.

Provided are methods for generating γδ T cells from induced pluripotent stem cells. Also provided are genetically engineered iPSCs, γδ T cells, CAR-γδ T cells, and methods of using the same.